Kornimate/medical-research-clean huggingface dataset:
short and medium-term effects of pulmonary rehabilitation in mild to critical post-acute covid-19

Conditions: Covid19; SARS-CoV Infection; Pulmonary Rehabilitation; Quality of Life

Summary: as a direct consequence of the covid-19 pandemic, it is assumed that the number of patients with covid-19-related disabilities will increase significantly. patients with mild, severe, and critical forms of the disease show long-term sequelae in different systems (respiratory, muscular, psychological, cognitive etc.). persistent dyspnea is a frequently described symptom after the acute phase of the disease. coupled with reduced oxygen saturation, an increased risk of developing lung fibrosis has been observed. specialized rehabilitation medicine (e.g. pulmonary rehabilitation) might counteract these long-term consequences and therefore seems to be a promising approach to treat long-term covid-19 consequences. further, there is scarce evidence about covid-19 specific rehabilitation contents. it was suggested to use treatment regimes in analogy to patients with idiopathic pulmonary fibrosis. there is evidence that pulmonary rehabilitation improves physical performance, quality of life and reduces anxiety and depression symptoms in patients with idiopathic pulmonary fibrosis and other chronic respiratory diseases. since impairments related to idiopathic pulmonary fibrosis also play an important role in covid-19, the aim of this study is to evaluate the short and medium-term effects of a standardized 3-week pulmonary rehabilitation program. the results will be analyzed within the two cohorts (mild/moderate and severe/critical covid 19) as well as between the two cohorts for the primary outcome. furthermore, the effects of pulmonary rehabilitation will be compared with a retrospective cohort of idiopathic pulmonary fibrosis.


Eligibility criteria:
inclusion criteria: * post-acute phase covid-19 patients with mild, moderate, severe or critical course * written informed consent exclusion criteria: * patients who are unable to walk
lymphadenectomy in ovarian neoplasms

Conditions: Ovarian Cancer

Summary: to assess the efficacy of systematic pelvic and para-aortic lymphadenectomy in patients with advanced ovarian cancer and intra-abdominal complete debulking. secondary: progression-free survival, complications and quality of life; exploratory: role of number of resected lymph nodes for primary and secondary objectives


Eligibility criteria:
inclusion criteria: * primary diagnosis of invasive epithelial ovarian cancer figo stage iib-iv (iv only if resectable metastasis in pleura, liver, spleen, and/or abdominal wall) * macroscopic complete resection * age: 18 - 75 years * patients who have given their signed and written informed consent * good performance status (ecog 0/1) exclusion criteria: * non epithelial ovarian malignancies and borderline tumors * intraoperative clinically suspicious lymph nodes (bulky nodes) * secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma figo ia g1/2, non melanoma skin cancer, breast cancer t1 n0 m0 g1/2) or with any signs of relapse or activity. * recurrent ovarian cancer * prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy * diseases of the lymph system (including lymph edema of unknown origin) * clinical relevant dysfunctions of blood clotting (including medicamentous conditioned reasons, e.g. ass, if not stopped at least 7 days prior to surgery) * any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator) * prior retroperitoneal lymph node dissection (systematic or sampling) * pregnancy * dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent * any reasons interfering with regular follow-up

Keywords: ovarian cancer, figo stage iib-iv
arsenic trioxide in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: additional active agents are needed to further improve the treatment of patients with cll/sll. increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for cll/sll. this study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory cll/sll

upon determination of eligibility, patients will receive: * arsenic trioxide

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * histologically proven b-cell cll/sll. * must have had a minimum of 1 and a maximum of 3 previous systemic regimens * must have progressive cll/sll * measurable or evaluable disease * ecog performance status 0, 1, or 2 * age \> 18 years. * patients with cytopenias caused by bone marrow involvement are eligible * all patients must give written informed consent prior to entering this study. exclusion criteria: you cannot participate in this study if any of the following apply to you: * unstable active infection on the basis of neutropenia * previous severe opportunistic infections * severe immune mediated anemia or thrombocytopenia * serious underlying medical conditions * brain metastases or meningeal involvement * history of other neoplasms * significant underlying heart dysfunction * women who are pregnant or please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
application of remote ischemic preconditioning in patients undergoing open heart surgeries

Conditions: Coronary Artery Disease; Valvular Heart Disease

Summary: strategies for myocardial protection during open heart surgeries are desired. several experimental studies have shown beneficial effects of remote ischemic preconditioning (ripc). the underlying mechanisms are not totally understood. this study intends to evaluate molecular mechanisms involved with ripc on myocardium of patients underwent open heart surgeries.


Eligibility criteria:
inclusion criteria: * patients older than 18 years * scheduled for coronary artery bypass grafting with or without valve replacement associated * use of blood cardioplegia * euroscore ii greater than or equal to 1.0% exclusion criteria: * history of cardiogenic shock * complications in the admission * pregnant patients * severe peripheral arterial disease affecting the upper limbs * liver failure (bilirubin ˃ 20 mmol / l, inr 2.0 ˃) * significant pulmonary disease (˂ fev1 40%) * renal failure with glomerular filtration rate ˂ ml/min/1,73 m² * concomitant treatment with glibenclamide or nicorandil (medications that interfere with cardioprotection induced by ipcr)

Keywords: ischemia reperfusion myocardial ischemia myocardial reperfusion
prognostic value of cardiac and renal markers in ischemic stroke and transient ischemic attack

Conditions: Ischemic Stroke; Transient Ischemic Attack

Summary: patients with stroke or transient ischemic attack (tia) are at high risk of poor outcome, recurrence of cardiovascular events or vascular death.until now, no reliable predictive biological marker could be identified in the acute phase of stroke.we hypothese that, in the acute phase of ischemic stroke or tia, the increase of cardiac ( brain natriuretic peptide, bnp) or renal markers (albuminuria, cystatin c)might predict recurrence of cardiovascular events or vascular death. we want to assess which one of these markers has the best prognosis value , in a prospective study of 300 stroke patients followed during 3 years.

patients with ischemic stroke or tia will be included in the 48 hours following the onset of symptoms, in 3 university hospitals.for each patient will be collected * 1 blood sample for the bnp measure in pg/ml * 1 blood sample for the cystatin c measure in mg/l * 2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days after the inclusion, and to study the variation of albuminuria in micrograms/min. the clinical follow-up will be organized during 3 years. the following events will be notified: poor outcome (defined with the barthel and rankin scores), recurrence of cardiovascular or cerebrovascular events, vascular death. after adjustment on the main clinical prognosis factors, we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the "high-risk" patients, in order to intensify individual treatment and secondary prevention.

Eligibility criteria:
inclusion criteria: * ischemic stroke or tia in the first 48 hours following the onset of symptoms exclusion criteria: * patient unable to give an informed consent * urinary sample impossible to collect

Keywords: stroke transient ischemic attack albuminuria bnp cystatin c
contribution of mri in the evaluation of apparent diffusion coefficient and prediction of response to neoadjuvant chemotherapy in breast cancer

Conditions: Assess the Variation of Apparent Diffusion Coefficient

Summary: the main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy


Eligibility criteria:
inclusion criteria: * age\> 18 years. * patient suffering from a breast tumor, regardless of the stage and size * patient requiring neoadjuvant chemotherapy * patient has the ability to undergo 18f-fdg-pet at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery * compulsory affiliation to a social security system. * obtaining informed consent in writing, signed and dated. exclusion criteria: * patient with cognitive or psychiatric disorders. * patient deprived of liberty by a court or administrative. * patient with signs against the achievement of mri, mammography and ultrasound * patient metastatic * patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer * pregnant women, current lactation * patient suffering from uncontrolled diabetes (\> 11 mmol / l)

Keywords: adc breast cancer complete pathological response
effects of high frequency rtms combined motor learning on upper limb motor function in subacute stroke

Conditions: Stroke, Acute; Hemiplegia

Summary: this study is to present the effect of a program combining high frequency repetitive transcranial magnetic stimulation with motor learning on upper limb motor function and grip strength and activities of daily motion in patients with subacute stroke. purpose : this study was to investigate the effects of high frequency repetitive transcranial magnetic stimulation combined with motor learning effects motor function and grip force for upper limbs and activities of daily living of subacute stroke patients. subjects : thirty individuals with subacute stroke, satisfying the selection criteria, were selected for this study. subject were randomly allocated into 14 high frequency repetitive transcarnial magnetic stimulation+motor learning group(experimental group), 16 sham repetitive transcranial magnetic stimulation+motor learning group(control group). intervention : 12 sessions, 3d/wk, 4week studies : upper limb functional assessment(fma-u/l, bbt), hand grip force assessment(disital hand dynamometer), activities daily of living assessment(k-mbi) evaluation : 1)pre test 2)post test


Eligibility criteria:
inclusion criteria: * hemiplegia from stroke * factors within six months of onset * found to have subcortex damage through diagnoses of magnetic resonance imaging(mri) * had motor defects on the damaged upper extremities * korean version mini mental state examination(mmse-k) score greater than 24 points exclusion criteria: * permanent damage such as heart vein * upper limb fractures * neurological damage such as parkinson's, multiple sclerosis * other reasons limiting upper limb movement * epilepsy or family history of epilepsy * wearing a metal tube in skull or pacemaker * the lesion at occipital lobe
using sugar water to relieve pain in infants

Conditions: Pain; Infant, Newborn; Diabetes

Summary: this study will examine the safety and effectiveness of sugar water to relieve pain in newborn infants during painful blood tests and injections. infants of diabetic mothers who receive repeated blood tests will be compared to infants of healthy mothers who receive routine painful procedures. we believe that administration of sucrose analgesia for every painful cutaneous procedure performed after delivery will result in less pain during the newborn infant screening test.


Eligibility criteria:
inclusion criteria: * healthy newborn infants ≥36 weeks gestation * infants born to mothers with diabetes (type 1, type 2, or gestational diabetes that is diet-controlled or insulin-dependent)and infants born to mothers without diabetes exclusion criteria: * admission to the neonatal intensive care unit * plan to undergo circumcision during the study period * major congenital or neurological anomalies * clinical diagnosis of birth asphyxia or seizures * receiving analgesics or sedatives

Keywords: sucrose analgesia pain neonates diabetes
an artificial intelligence assisted telehealth intervention to promote self-management in patients with type 2 diabetes mellitus (qualitative interview)

Conditions: Diabetes Mellitus

Summary: this protocol involves a qualitative study of the needs/preferences of people with diabetes and health coaches regarding a telehealth coaching platform for glycemic control in people with diabetes.


Eligibility criteria:
inclusion criteria: health coaches group: (i) age between 18 and 80 years (ii) fluent in english (iii) work in or carry expertise in physical activity, nutrition/diet or health behavior. people with diabetes group (patient/caregiver dyads): (i) age between 18 and 80 years (ii) fluent in english (iii) have type-ii diabetes. exclusion criteria: none
correlation of family history, age at onset & severity of stuttering

Conditions: Stuttering, Childhood

Summary: the aim of this study is to detect the influence of the family history of stuttering (distance of relative) on the onset and severity of stuttering in children in these families. also to explore developmental differences among young stutterers.


Eligibility criteria:
inclusion criteria: * 1-age: from 7 to 15 years old. 2-gender: both sexes will be included in the study. 3-the participants are diagnosed as stutterers by an expert phoniatrician. 4-children will be accepted only if full information is provided concerning the presence or absence of family history of stuttering, from both paternal and maternal sides of the family, and the age of onset of stuttering manifestations. 5-mentality: iq is 80 or more exclusion criteria: * 1-age below 7 years or above 15 years. 2-failure to provide full information concerning the presence or absence of family history of stuttering, from both paternal and maternal sides of the family, or age of onset of stuttering manifestations.. 3- iq less than 80
outcomes of femoro-popliteal disease after stent deployment under intravascular ultrasound guidance

Conditions: Peripheral Arterial Disease

Summary: this is a prospective, single-center study. the patients with peripheral arterial disease who underwent abdominal aortograms with runoff (which are arteriograms of the lower abdominal aorta and arteries in the legs) and intravascular ultrasound after stent deployment will be enrolled in the study. all patients who participated in the study will be treated according to standard of care. hypothesis the higher degree of plaque burden on landing zone has an effect on restenosis on peripheral artery intervention. specific aims 1. to determine intravascular ultrasound parameters of stent deployment and outcomes of femoro-popliteal disease 2. to determine clinical risk factors and outcomes of femoro-popliteal disease 3. to obtain data that will eventually support development of a predictive model for isr in femoro-popliteal disease methodology visit 1: after consent is given the subject will receive standard follow-up care. a member of the research team will collect information such as the subject's age, sex, ethnicity, and medical information from the subject's medical record. visits 2-5: 1 day after enrollment, and at months 3 (+- 2 weeks), 6 (+- 2 weeks), and 12 (+- 2 weeks) the subject will complete standard follow-up appointment at ttuhsc. this may include a doppler ultrasound. a member of the research team will record information such as medications, ultrasounds, and need for additional care related to the subject's stent. the subject will complete the questionnaire on leg pain and mobility.

subject population: - the patients who have peripheral arterial disease and underwent elective abdominal aortograms with runoff with peripheral artery intervention in university medical center hospital, lubbock texas, during january 2014 to december 30, 2015. inclusion criteria: * 25-89 years of age * admitted for elective abdominal aortograms with runoff. * underwent angioplasty and/or atherectomy with stent placement for femoro-popliteal disease. * intravascular ultrasound was performed after stent deployment. exclusion criteria: * patients who had prior femoro-popliteal artery surgery or bypass in the same limb. * stent placement for lesions above inguinal ligament or below popliteal artery. * the patient who presented with acute limb ischemia. * unable to follow-up in ttuhsc clinic.

Eligibility criteria:
inclusion criteria: * 25-89 years of age * admitted for elective abdominal aortograms with runoff. * underwent angioplasty and/or atherectomy with stent placement for femoro-popliteal disease. * intravascular ultrasound was performed after stent deployment. exclusion criteria: * patients who had prior femoro-popliteal artery surgery or bypass in the same limb. * stent placement for lesions above inguinal ligament or below popliteal artery. * the patient who presented with acute limb ischemia. * unable to follow-up in ttuhsc clinic.

Keywords: ivus pad femoro-popliteal disease intravascular ultrasound
sustainable hypertension management in primary health care in sweden

Conditions: Hypertension

Summary: new sustainable models of patient-focused and team-based care for patients with hypertension should be developed to achieve health improvements and cost-efficiency. the aim of this project is to evaluate new ways of sustainable hypertension (ht) management in primary care, starting with a pilot study at 2 primary health care centres (phccs). at intervention phccs cardiovascular risk is assessed with score2 for all hypertension patients. the staff receives education on ht treatment and an easy-to-follow treatment protocol. non-physicians lead patient education on ht in groups. patients receive a home blood pressure (bp) monitor and communicate digitally with the assigned nurse on medication update, blood and urinary tests and follow up. the nurse consults with the physician if needed. regular face to face visits with the physician are only scheduled for patients with high cardiovascular risk or end organ damage, otherwise for all patients if needed. at the control phcs hypertension care continues as usual. all participants will be asked to complete questionnaires after 6 and 24 months. outcomes are feasibility for the pilot study and the proportion of patients reaching bp target plus change in systolic bp, cardiovascular risk factors, patients´ and staff´s grade of satisfaction and knowledge, and health care costs for the main study, compared between intervention and control phccs. results will help to establish sustainable models of treating ht patients in primary care.


Eligibility criteria:
inclusion criteria: - adult patients with hypertension exclusion criteria: * secondary hypertension according to the medical records at the primary health care center * terminal illness * pregnancy-induced hypertension * cognitive impairment * impaired vision (not able to read measurements for the home bp measurements or communicate via "1177 direct" digitally) * psychotic disorder

Keywords: primary health care management
thalidomide with or without probiotics in radioactive oral mucositis

Conditions: Oral Mucositis; Quality of Life

Summary: study on the application of thalidomide with or without probiotics in radioactive oral mucositis

radiation oral mucositis is an acute mucous membrane reaction in patients undergoing radiotherapy of the head and neck. it can cause dose limitation and debilitating side effects. there is no accepted guideline that can significantly reduce its severity. in the mucosa, t and b cells of the immune system have location-specific phenotypes and functions that are influenced by the microbiome. these cells play a key role in maintaining immune homeostasis by inhibiting responses to harmless antigens and enhancing the integrity of intestinal mucosal barrier function. we designed a clinical study of thalidomide with or without probiotics in radioactive oral mucositis. the aim of this study was to determine whether regulation of intestinal flora can effectively reduce the severity of radiation-induced mucositis in patients undergoing radical radiation therapy. the researchers also investigated the effect of the intervention on patients' general well-being. the primary endpoint was the incidence of grade 3 mucositis in the radiotherapy oncology group. in 2021, an estimated 40 patients were enrolled in the study at jiangxi cancer hospital in china.

Eligibility criteria:
inclusion criteria: * karnofsky score ≥80 ,newly diagnosed npc without distant metastasis, confirmed by pathology without any other malignant disease history ,no any other anti-cancer treatment for npc previously ,received radiotherapy and chemotherapy at our cancer center exclusion criteria: * any immune system disease under high risk to antimicrobial agents such as diabetes,infection disease
prediction of response to treatment with immunotherapy + chemotherapy in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this study seeks to evaluate a multiparametric test including 6 immunohistochemical markers (pd-l1, cd8, foxp3, pd1, cd163, cd15) to predict the cumulative incidence of death or progression on treatment with pembrolizumab+first line chemotherapy in metastatic non-small cell lung cancer, regardless of the pd-l1 status and in the absence of alk, ros1 or egfr alteration.


Eligibility criteria:
inclusion criteria: * 18 years at time of diagnosis * affiliation to a social insurance * obtaining the patient's non opposition * patients with non-small cell lung carcinoma, confirmed by anatomopathological, metastatic or locally advanced unresectable, not eligible for local curative treatment * cellular or tissue ffpe available * indication of treatment with pembrolizumab + first line chemotherapy in multidisciplinary consultation meeting * no mutation of the egfr gene, no rearrangement of alk and ros, * at least one measurable tumor according to recist criteria exclusion criteria: * tissue or cellular ffpe not available * systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or adjuvant treatment completed 6 months or more